Osteoarthritis (OA) is one of the common degenerative joint diseases in clinic. It mainly damages articular cartilage, causing pain, swelling and stiffness around joints, and is the main cause of disability of the elderly. Due to the unclear pathogenesis of osteoarthritis and the poor self-healing ability of articular cartilage, the treatment options for this disease are limited. At present, NSAIDs, Glucocorticoid and Duloxetine are the most commonly used treatment choice for osteoarthritis. Although it is somewhat effective, the adverse reactions are frequent and serious. The development of safer and more effective anti-osteoarthritis drugs is essential and urgent. This review summarizes recent advances in the pharmacological treatment of OA, focusing on small molecule inhibitors targeting cartilage remodeling in osteoarthritis as well as the research idea of reducing adverse effects by optimizing the dosage form of traditional drugs for the treatment of osteoarthritis. It should provide a reference for exploration of new potential treatment options.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119395PMC
http://dx.doi.org/10.3389/fphys.2023.1156913DOI Listing

Publication Analysis

Top Keywords

small molecule
8
molecule inhibitors
8
articular cartilage
8
treatment options
8
osteoarthritis
6
treatment
5
inhibitors osteoarthritis
4
osteoarthritis current
4
current development
4
development future
4

Similar Publications

Background Aims: The clinical translation of mesenchymal stromal cell secretome (MSC-S) has been challenging owing to a lack of appropriate methods in downstream processing. Dialysis is an age-old method of protein purification by the exchange of small molecules through a semi-permeable membrane. In this study, we investigated the potential of three forms of umbilical cord-derived MSC secretome (UC-MSC-S)-native (S), dialyzed (DS), and lyophilized (LDS)-for wound healing applications.

View Article and Find Full Text PDF

CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling.

Int J Biol Macromol

January 2025

Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian 223300, Jiangsu Province, PR China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, PR China. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in adults, which characterized by a high degree of heterogeneity in terms of clinical presentation, molecular phenotype, and genetic features. However, approximately 30 %-40 % of patients are refractory to standard chemotherapy, and their prognosis is poor. The emergence of small-molecule inhibitors, such as Bruton's tyrosine kinase inhibitors (BTKi), has greatly improved the treatment of DLBCL; however, drug resistance associated with small-molecule inhibitors has greatly limited their clinical application.

View Article and Find Full Text PDF

The riverine dissolved organic matter (DOM) pool constitutes the largest and most dynamic organic carbon reservoir within inland aquatic systems. Human activities significantly alter the distribution of organic matter (OM) in rivers, thereby affecting the availability of DOM. However, the impact of total suspended solids (TSS) on DOM under anthropogenic influence remains insufficiently elucidated.

View Article and Find Full Text PDF

This paper introduces a highly absorbent and sensitive cellulose nanofiber (CNF)/gold nanorod (GNR)@Ag surface-enhanced Raman scattering (SERS) sensor, fabricated using the vacuum filtration method. By optimizing the Ag thickness in the GNR@Ag core-shell structures and integrating them with CNFs, optimal SERS hotspots were identified using the Raman probe molecule 4-aminothiophenol (4-ATP). To concentrate pesticides extracted from fruit and vegetable surfaces, we utilized the evaporation enrichment effect using hydrophilic CNF and hole-punched hydrophobic polydimethylsiloxane (PDMS).

View Article and Find Full Text PDF

Discovery of CZY43 as a new small-molecule degrader of pseudokinase HER3.

Eur J Med Chem

January 2025

State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd, Shanghai, 200032, China. Electronic address:

The pseudokinase HER3 emerges as a promising anti-cancer target, especially for HER2-driven breast cancer and EGFR-mediated non-small cell lung cancer. However, it is challenging to target HER3 by ATP-competitive small molecules because HER3 is catalytically impaired. Herein, we report the discovery of a series of HER3 degraders by connecting a HER3 binder bosutinib with a hydrophobic tag adamantane.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!